Evidence map›Paper›PMID 39574509›Full record

ArticleFrontiers in neurology2024

Plasma symmetric dimethylarginine as a metabolite biomarker of severe acute ischemic stroke.

Saana Pihlasviita, Olli S Mattila, Tiina Nukarinen, Markku Kuisma, Heini Harve-Rytsälä, Juhani Ritvonen, Gerli Sibolt, Sami Curtze, Daniel Strbian, Mikko Pystynen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Saana PihlasviitaNeurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Olli S MattilaNeurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tiina NukarinenNeurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Markku KuismaEmergency Medicine and Services, Department of Emergency Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Heini Harve-RytsäläEmergency Medicine and Services, Department of Emergency Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Juhani RitvonenNeurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Gerli SiboltNeurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Sami CurtzeNeurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Daniel StrbianNeurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Mikko PystynenEmergency Medicine and Services, Department of Emergency Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Turgut TatlisumakDepartment of Clinical Neuroscience/Neurology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Perttu J LindsbergNeurology and Clinical Neurosciences, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: After severe ischemic stroke (IS), circulating levels of symmetric dimethylarginine (SDMA) increase. We investigated the early dynamics of SDMA in stroke to potentially aid with prehospital identification of severe IS from hemorrhagic stroke (HS). Methods: We performed targeted mass spectrometry (MS) measurements of SDMA in two sequential acute plasma samples (early and secondary) of 50 IS patients with LVO and 49 HS patients. Secondary samples of 227 IS and 84 HS patients with moderate to severe symptoms (NIHSS ≥ 7) subsequently underwent ELISA validation. Results: The median (IQR) last-known-well (LKW) to sampling times were 43 min (35-67) for early samples in the MS analysis, and 83 min (65-113) for secondary samples in MS and ELISA analyses. No inter-group differences existed in early samples, but IS patients had significantly higher mean (IQR) SDMA levels in secondary samples in both analyses: 5.8 (5.3-6.9) vs. 5.1 (4.2-5.8) A.U. for HS, Conclusion: In a large clinical cohort of stroke patients with moderate to severe symptoms, our data suggest that SDMA can assist in differentiation of IS and HS patients already 1 h and a half after symptom onset. SDMA may prove to have future value in a diagnostic stroke biomarker panel.

Indexed as

acute managementbiomarkersdiagnosisSDMAstroke

Identifiers

PMID39574509
PMCPMC11578963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.